- Home
- BYSI vs CLNN Comparison
BYSI vs CLNN Comparison
Compare BYSI & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYSI | CLNN |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 48.4M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | BYSI | CLNN |
|---|---|---|
| Price | $1.45 | $5.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 20.7K | ★ 61.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $2.28 |
| 52 Week High | $3.44 | $13.50 |
Technical Indicators
Market Signals| Indicator | BYSI | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 57.09 |
| Support Level | $1.38 | $3.43 |
| Resistance Level | $1.81 | $5.71 |
| Average True Range (ATR) | 0.10 | 0.45 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 67.65 | 84.71 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.